The FDA has won a petition to have the US Court of Appeals for the District of Columbia reconsider a ruling that mentally competent terminally ill patients should have access to post-Phase I investigational drugs if there are no government-approved alternatives.
The FDA has won a petition to have the US Court of Appeals for the District of Columbia reconsider a ruling that mentally competent terminally ill patients should have access to post-Phase I investigational drugs if there are no government-approved alternatives.
From the January 01, 2007 Issue of MM+M - Medical Marketing and Media
Get the most out of 
Register for free and enjoy unlimited access to:
